Please use this identifier to cite or link to this item:
Title: Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study
Author: Nounu, Aayah
Richmond, Rebecca C.
Stewart, Isobel D.
Surendran, Praveen
Wareham, Nicholas J.
Butterworth, Adam
Weinstein, Stephanie J.
Albanes, Demetrius
Baron, John A.
Hopper, John L.
Figueiredo, Jane C.
Newcomb, Polly A.
Lindor, Noralane M.
Casey, Graham
Platz, Elizabeth A.
Marchand, Loïc Le
Ulrich, Cornelia M.
Li, Christopher I.
Van Dujinhoven, Fränzel J. B.
Gsur, Andrea
Campbell, Peter T.
Moreno Aguado, Víctor
Vodicka, Pavel
Vodickova, Ludmila
Amitay, Efrat L.
Alwers, Elizabeth
Chang Claude, Jenny
Sakoda, Lori C.
Slattery, Martha L.
Schoen, Robert E.
Gunter, Marc J.
Castellví Bel, Sergi
Kim, Hyeong Rok
Kweon, Sun Seog
Chan, Andrew T.
Li, Li
Zheng, Wei
Bishop, D. Timothy
Buchanan, Daniel D.
Giles, Graham G.
Gruber, Stephen B.
Rennert, Gad
Stadler, Zsofia K.
Harrison, Tabitha A.
Lin, Yi
Keku, Temitope O.
Woods, Michael O.
Schafmayer, Clemens
Van Guelpen, Bethany
Gallinger, Steven
Hampel, Heather
Berndt, Sonja I.
Pharoah, Paul D. P.
Lindblom, Annika
Wolk, Alicja
Wu, Anna H.
White, Emily
Peters, Ulrike
Drew, David A.
Scherer, Dominique
Bermejo, Justo Lorenzo
Brenner, Hermann
Hoffmeister, Michael
Williams, Ann C.
Relton, Caroline L.
Keywords: Càncer colorectal
Factors de risc en les malalties
Colorectal cancer
Risk factors in diseases
Issue Date: 21-Nov-2021
Publisher: MDPI AG
Abstract: Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes; (2) pathway SNPs present in enzymes' coding regions; and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84-1.27 and OR: 1.08, 95% CI: 0.86-1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.
Note: Reproducció del document publicat a:
It is part of: Nutrients, 2021, vol. 13, num. 11, p. 4164
Related resource:
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
nutrients-13-04164-v4.pdf1.63 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons